{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T14:22:37Z","timestamp":1776090157777,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":1772,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","exphem.org","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.exphem.2017.04.011","type":"journal-article","created":{"date-parts":[[2017,5,4]],"date-time":"2017-05-04T18:32:06Z","timestamp":1493922726000},"page":"65-71","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Development of an assay for cellular efflux of pharmaceutically active agents and its relevance to understanding drug interactions"],"prefix":"10.1016","volume":"52","author":[{"given":"Benigno C.","family":"Valdez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moustapha","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Borje S.","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2017.04.011_bib1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/BF00686213","article-title":"Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics","volume":"33","author":"Hassan","year":"1993","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.exphem.2017.04.011_bib2","first-page":"2083","article-title":"Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation. GITMO (Gruppo Italiano Trapianto di Midollo Osseo)","volume":"16","author":"Buggia","year":"1996","journal-title":"Anticancer Res"},{"key":"10.1016\/j.exphem.2017.04.011_bib3","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/sj.bmt.1702377","article-title":"The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: Time interval influence on therapeutic efficacy and therapy-related toxicity","volume":"25","author":"Hassan","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.exphem.2017.04.011_bib4","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/bmt.2011.75","article-title":"Deferasirox increases Bu blood concentrations","volume":"47","author":"Sweiss","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.exphem.2017.04.011_bib5","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/sj.bmt.1703896","article-title":"The effect of metronidazole on busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation","volume":"31","author":"Nilsson","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.exphem.2017.04.011_bib6","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1345\/aph.1Q087","article-title":"Busulfan and metronidazole: An often forgotten but significant drug interaction","volume":"45","author":"Gulbis","year":"2011","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.exphem.2017.04.011_bib7","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1007\/s11096-015-0197-x","article-title":"A case of melphalan sustained accumulation in an 80-year old patient","volume":"37","author":"Jolivot","year":"2015","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.exphem.2017.04.011_bib8","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/bjc.1995.230","article-title":"Flunarizine enhancement of melphalan activity against drug-sensitive\/resistant rhabdomyosarcoma","volume":"71","author":"Castellino","year":"1995","journal-title":"Br J Cancer"},{"key":"10.1016\/j.exphem.2017.04.011_bib9","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1600-0609.2010.01570.x","article-title":"Imatinib increases cytotoxicity of melphalan and their combination allows an efficient killing of chronic myeloid leukemia cells","volume":"86","author":"Giallongo","year":"2011","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.exphem.2017.04.011_bib10","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/j.leukres.2008.01.016","article-title":"Altered gene expression in busulfan-resistant human myeloid leukemia","volume":"32","author":"Valdez","year":"2008","journal-title":"Leuk Res"},{"key":"10.1016\/j.exphem.2017.04.011_bib11","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.exphem.2017.04.011_bib12","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.leukres.2003.10.015","article-title":"Evaluation and comparison of MRP1 activity with three fluorescent dyes and three modulators in leukemic cell lines","volume":"28","author":"Dogan","year":"2004","journal-title":"Leuk Res"},{"key":"10.1016\/j.exphem.2017.04.011_bib13","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1016\/0006-2952(82)90097-1","article-title":"Enhancement of vincristine- and adriamycin-induced cytotoxicity by verapamil in P388 leukemia and its sublines resistant to vincristine and adriamycin","volume":"31","author":"Tsuruo","year":"1982","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.exphem.2017.04.011_bib14","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1006\/bbrc.1995.1344","article-title":"The leukotriene LTD4 receptor antagonist MK571 specifically modulates MRP associated multidrug resistance","volume":"208","author":"Gekeler","year":"1995","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.exphem.2017.04.011_bib15","first-page":"31","article-title":"Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics","volume":"16","author":"Slattery","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.exphem.2017.04.011_bib16","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2217\/pgs.12.185","article-title":"Role of pharmacogenetics in busulfan\/cyclophosphamide conditioning therapy prior to hematopoietic stem cell transplantation","volume":"14","author":"Hassan","year":"2013","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.exphem.2017.04.011_bib17","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/sj.cdd.4400959","article-title":"Role of glutathione depletion and reactive oxygen species generation in apoptotic signaling in a human B lymphoma cell line","volume":"9","author":"Armstrong","year":"2002","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.exphem.2017.04.011_bib18","doi-asserted-by":"crossref","first-page":"e229","DOI":"10.1038\/bcj.2014.45","article-title":"The glutathione synthesis inhibitor buthionine sulfoximine synergistically enhanced melphalan activity against preclinical models of multiple myeloma","volume":"4","author":"Tagde","year":"2014","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.exphem.2017.04.011_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00647438","article-title":"Comparative activity of ifosfamide and cyclophosphamide","volume":"18 Suppl 2","author":"Brade","year":"1986","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.exphem.2017.04.011_bib20","doi-asserted-by":"crossref","first-page":"627","DOI":"10.2174\/1381612805666230110215458","article-title":"The chemistry of the metabolites of cyclophosphamide","volume":"5","author":"Ludeman","year":"1999","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.exphem.2017.04.011_bib21","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/0006-2952(89)90419-X","article-title":"The effect of ifosfamide and its metabolites on intracellular glutathione levels in\u00a0vitro and in\u00a0vivo","volume":"38","author":"Lind","year":"1989","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.exphem.2017.04.011_bib22","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/BF02994088","article-title":"Cellular glutathione as a protective agent against 4-hydroperoxycyclophosphamide cytotoxicity in K-562 cells","volume":"26","author":"Peters","year":"1990","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.exphem.2017.04.011_bib23","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/00001813-199408000-00003","article-title":"Ifosfamide induced depletion of glutathione in human peripheral blood lymphocytes and protection by mesna","volume":"5","author":"Meier","year":"1995","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.exphem.2017.04.011_bib24","doi-asserted-by":"crossref","first-page":"20114","DOI":"10.1074\/jbc.273.32.20114","article-title":"Coordinated action of glutathione S-transferases (GSTs) and multidrug resistance protein 1 (MRP1) in antineoplastic drug detoxification: Mechanism of GST A1-1- and MRP1-associated resistance to chlorambucil in MCF7 breast carcinoma cells","volume":"273","author":"Morrow","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.exphem.2017.04.011_bib25","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S0006-2952(98)00240-8","article-title":"Combined expression of multidrug resistance protein (MRP) and glutathione S-transferase P1-1 (GSTP1-1) in MCF7 cells and high level resistance to the cytotoxicities of ethacrynic acid but not oxazaphosphorines or cisplatin","volume":"56","author":"Morrow","year":"1998","journal-title":"Biochem Pharmacol"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X17301431?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X17301431?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T12:13:50Z","timestamp":1692792830000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X17301431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":25,"alternative-id":["S0301472X17301431"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2017.04.011","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of an assay for cellular efflux of pharmaceutically active agents and its relevance to understanding drug interactions","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2017.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of ISEH - International Society for Experimental Hematology.","name":"copyright","label":"Copyright"}]}}